Abstract
Background While safety of influenza vaccines is well-established, some studies have suggested potential associations between influenza vaccines and certain adverse events (AEs). This study examined the safety of the 2022–2023 influenza vaccines among U.S. adults ≥ 65 years.
Methods A self-controlled case series compared incidence rates of anaphylaxis, encephalitis/encephalomyelitis, Guillain Barré-Syndrome (GBS), and transverse myelitis following 2022–2023 seasonal influenza vaccinations (i.e., any, high-dose or adjuvanted) in risk and control intervals among Medicare beneficiaries ≥ 65 years. We used conditional Poisson regression to estimate incidence rate ratios (IRRs) and 95% confidence intervals (CIs) adjusted for event-dependent observation time, seasonality, and outcome misclassification. For AEs with any statistically significant associations, we stratified results by concomitant vaccination status.
Results Among 12.7 million vaccine recipients, we observed 76 anaphylaxis, 276 encephalitis/encephalomyelitis, 134 GBS and 75 transverse myelitis cases. Only rates of anaphylaxis were elevated in risk compared to control intervals. With all adjustments, an elevated, but non-statistically significant, anaphylaxis rate was observed following any (IRR: 2.40, 95% CI: 0.96–6.03), high-dose (IRR: 2.31, 95% CI: 0.67–7.91), and adjuvanted (IRR: 3.28, 95% CI: 0.71–15.08) influenza vaccination; anaphylaxis IRRs were 2.54 (95% CI: 0.49–13.05) and 1.64 (95% CI: 0.38–7.05) for those with and without concomitant vaccination, respectively.
Conclusions Rates of encephalitis/encephalomyelitis, GBS, or transverse myelitis were not elevated following 2022–2023 seasonal influenza vaccinations among U.S. adults ≥ 65 years. There was an increased rate of anaphylaxis following influenza vaccination that may have been influenced by concomitant vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://bestinitiative.org/wp-content/uploads/2023/06/BEST_2022-2023_Influenza-AE_Protocol_2023.pdf
Funding Statement
The US Food and Drug Administration provided funding for this study and contributed as follows: led the design of the study, interpretation of the results, writing of the manuscript, decision to submit, and made contributions to the coordination of data collection and analysis of the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We conducted this study within the Biologics Effectiveness and Safety (BEST) Initiative. FDA Amendments Act of 2007 required that FDA develop a national electronic system for monitoring safety of FDA-regulated medical products. FDA built the Sentinel Initiative in response to the congressional requirement, and the BEST Initiative commenced as a Center for Biologics Evaluation and Research (CBER) component of Sentinel. The Office of Human Research Protection (OHRP) determined that the regulations OHRP administers (45 CFR part 46) do not apply to the activities that are included in the FDA's Sentinel Initiative.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Affiliation Addresses:
Acumen, LLC
500 Airport Blvd. Suite 100
Burlingame, CA 94010
United States
Office of Biostatistics and Pharmacovigilance
Center for Biologics Evaluation and Research
U. S. Food & Drug Administration
10903 New Hampshire Ave., Building 71
Silver Spring, MD 20993
United States
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop B3-30-03
Baltimore, Maryland 21244-1850
United States
Author Email Addresses: Xiangyu (Chianti) Shi (xshi{at}acumenllc.com), Joann F. Gruber (Joann.Gruber{at}fda.hhs.gov), Michelle Ondari (mondari{at}acumenllc.com), Patricia C. Lloyd (Patricia.Lloyd{at}fda.hhs.gov), Pablo Freyria Duenas (pduenas{at}acumenllc.com), Tainya C. Clarke (Tainya.Clarke{at}fda.hhs.gov), Gita Nadimpalli (gnadimpalli{at}acumenllc.com), Sylvia Cho (Sylvia.Cho{at}fda.hhs.gov), Laurie Feinberg (lfeinberg{at}acumenllc.com), Mao Hu, (mhu{at}acumenllc.com), Yoganand Chillarige (ychillarige{at}acumenllc.com), Jeffrey A. Kelman (Jeffrey.Kelman{at}cms.hhs.gov) Richard A. Forshee (Richard.Forshee{at}fda.hhs.gov), Steve A. Anderson (Steven.Anderson{at}fda.hhs.gov), Azadeh Shoaibi (Azadeh.Shoaibi{at}fda.hhs.gov)
Main Point: This study assessed the safety of the 2022–2023 seasonal influenza vaccines administered to U.S. adults 65 years and older. An elevation in the rate of anaphylaxis was identified following influenza vaccination, with a potential association with concomitant vaccination.
Data Availability
All data described in the present study is not available to protect patient confidentiality.
